comparemela.com

Latest Breaking News On - Zeneca pharma - Page 8 : comparemela.com

Nifty, Sensex shows no signs of tiring – Wednesday closing report

Nifty, Sensex shows no signs of tiring – Wednesday closing report Moneylife Digital Team / IANS  0 We had mentioned in Tuesday’s closing report that Nifty, Sensex were trending up. On Wednesday, the major indices made minor gains. On the NSE, there were 1,002 advances, 859 declines and 363 unchanged.   The trends of the major indices in the course of Wednesday’s trading are given in the table below:     UPL pre-paid $410 million of its 3.25% senior notes due October 2021 using the cash on its balance sheet.     Kalpataru Power Transmission bagged new orders in T&D business and EPC of about Rs 900 crore.    JMC Projects (India) got orders of Rs 698 crore for building works in South India. The company said their order inflow for the current year has crossed Rs 6,700 crore.

India
United-kingdom
Israel
Coromandel
India-general
Britain
Astrazeneca-pharma
Welspun-corp
Moneylife-digital-team
Nuclear-power-corporation-of-india-limited
Coromandel-international
Oxford-university

Market LIVE: Sensex 46K, Nifty tops 13,500; Infosys soars as IT stocks rally

Sensex zooms 437 points, Nifty ends above 13,600; broader indices outperform Indian stock markets rebounded on Tuesday, clawing back some of the losses from a brutal sell-off in the previous session. (Photo: Reuters) 12 min read Having opened in the red, Indian benchmark indices quickly reversed losses to surge higher on Wednesday. The Sensex today hit a high of 46,513.32 and a low 45,899.10, while the Nifty moved in the range of 13,432.20-13,619.45 Share Via 23 Dec 2020, 03:48:58 PM IST FMCG, IT stocks lead market rally; Sensex, Nifty soar 1% each Indian equity markets rose nearly 1% on Wednesday led by strong gains in IT, FMCG, realty stocks and PSU banks.

Germany
Australia
Japan
Mumbai
Maharashtra
India
United-kingdom
Texas
United-states
Washington
Oxford-astrazeneca
Sameet-chavan

Nifty, Sensex may continue its upmove – Wednesday closing report

Nifty, Sensex may continue its upmove – Wednesday closing report Moneylife Digital Team  1 We had mentioned in Tuesday’s closing report that Nifty, Sensex may try to move up. On Wednesday, the major indices continued to climb higher.     The trends of the major indices in the course of Wednesday’s trading are given in the table below:     Infosys bagged a multi-year technology contract from Germany’s Daimler AG, with the deal size estimated at a billion dollars.    Ramco Systems has signed a multi-million dollar agreement with a global Fortune 500 major to unify and transform its payroll for 18 countries in the Asia- Pacific region on Ramco’s Managed Payroll Services.

India
Germany
Ashok-nagar
Madhya-pradesh
Shivpuri
Uttaranchal
Udhampur
Uttar-pradesh
Glenmark-pharma
Dilip-buildcon
Astrazeneca-pharma
Balram-garg

Gainers & Losers: 10 Stocks That Moved The Most On December 23

Gainers & Losers: 10 stocks that moved the most on December 23 Mid and smallcaps outperformed largecaps. BSE midcap and smallcap indices rose 2.40 percent and 2.65 percent, respectively. December 23, 2020 / 04:52 PM IST The market logged healthy gains on December 23 amid mixed global cues. The Sensex closed 437 points, or 0.95%, higher at 46,444.18 and the Nifty gained 135 points, or 1%, at 13,601.10. Ramco Systems | CMP: Rs 605.90 | The stock price jumped more than 6 percent after the company bagged a multi-million dollar deal. Ramco Systems has signed a multi-million dollar agreement with a global Fortune 500 major to unify and transform its payroll for 18 countries in the Asia- Pacific region on Ramco’s Managed Payroll Services, the company said in an exchange filing.

Germany
Vadodara
Gujarat
India
Delhi
Switzerland
Ntakli
Maharashtra
German
Swiss
Oxford-astrazeneca
Nayagoan-jaqeer

AstraZeneca Pharma gets DCGI nod to market asthma drug

URL copied AstraZeneca Pharma gets DCGI nod to market asthma drug Drug firm AstraZeneca Pharma on Monday said it has received marketing authorisation from Drug Controller General of India for Benralizumab solution, indicated as an add-on maintenance treatment for severe asthma. AstraZeneca Pharma India Ltd has received import and market permission in Form CT-20 (marketing authorisation) from the Drugs Controller General of India for Benralizumab 30mg/ml solution for injection (Fasenra), the drug firm said in a regulatory filing.  Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients. AstraZeneca Pharma said the receipt of this permission paves way for the launch of Benralizumab (Fasenra) in India, subject to the receipt of related statutory approvals and licenses.

India
Benralizumab-fasenra
Astrazeneca-pharma
Astrazeneca-pharma-india-ltd
Image-source
Drug-controller-general
Zeneca-pharma-india-ltd
Drugs-controller-general
Zeneca-pharma
Astrazeneca-pharma-india
இந்தியா
படம்-மூல

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.